By adopting single cell RNA sequencing protocols, we are studying the complex architecture of lung cancer microenvironments in both clinical and preclinical settings. In particular, we are investigating the transformed epithelial component, the tumor infiltrating immune cells, as well as the tumor-associated fibroblasts and endothelial cells. Our aim is identifying improved precision medicine protocols for lung cancer.